Abstract:Transforming growth factor beta (TGF beta) induces hepatic stellate cell (HSC) differentiation into tumor-promoting myofibroblast, although underlying mechanism remains incompletely understood. Focal adhesion kinase (FAK) is activated in response to TGF beta stimulation, so it transmits TGF beta stimulus to extracellular signal-regulated kinase and P38 mitogen-activated protein kinase signaling. However, it is unknown whether FAK can, in return, modulate TGF beta receptors. In this study, we tested whether FAK phosphorylated TGF beta receptor 2 (TGF beta R2) and regulated TGF beta R2 intracellular trafficking in HSCs. The FAKY397F mutant and PF-573,228 were used to inhibit the kinase activity of FAK, the TGF beta R2 protein level was quantitated by immunoblotting, and HSC differentiation into myofibroblast was assessed by expression of HSC activation markers, alpha-smooth muscle actin, fibronectin, or connective tissue growth factor. We found that targeting FAK kinase activity suppressed the TGF beta R2 protein level, TGF beta 1-induced mothers against decapentaplegic homolog phosphorylation, and myofibroblastic activation of HSCs. At the molecular and cellular level, active FAK (phosphorylated FAK at tyrosine 397) bound to TGF beta R2 and kept TGF beta R2 at the peripheral plasma membrane of HSCs, and it induced TGF beta R2 phosphorylation at tyrosine 336. In contrast, targeting FAK or mutating Y336 to F on TGF beta R2 led to lysosomal sorting and degradation of TGF beta R2. Using RNA sequencing, we identified that the transcripts of 764 TGF beta target genes were influenced by FAK inhibition, and that through FAK, TGF beta 1 stimulated HSCs to produce a panel of tumor-promoting factors, including extracellular matrix remodeling proteins, growth factors and cytokines, and immune checkpoint molecule PD-L1. Functionally, targeting FAK inhibited tumor-promoting effects of HSCs in vitro and in a tumor implantation mouse model. Conclusion: FAK targets TGF beta R2 to the plasma membrane and protects TGF beta R2 from lysosome-mediated degradation, thereby promoting TGF beta-mediated HSC activation. FAK is a target for suppressing HSC activation and the hepatic tumor microenvironment.

Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis.

PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/-catenin signalling pathway

Focal Adhesion Kinase Promotes Hepatic Stellate Cell Activation by Regulating Plasma Membrane Localization of TGFβ Receptor 2.

Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis

[Effect of Antisense Oligonucleotides Targeting Focal Adhesion Kinase on the Proliferation and Activation of Hepatic Stellate Cells].

Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway

Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells

Influence of FAK inhibitors to human hepatic stellate cells by Akt/GSK-3β/β-catenin signal pathway

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

F-actin Cytoskeleton Reorganization is Associated with Hepatic Stellate Cell Activation

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

Targeting Src Family Kinase Member Fyn by Saracatinib Attenuated Liver Fibrosis in Vitro and in Vivo.

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis

KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway

Fibroblast growth factor 18 attenuates liver fibrosis and HSCs activation via the SMO-LATS1-YAP pathway

Transforming Growth Factor-β Pathway and Molecular Treatment of Liver Fibrosis

Hepatic stellate cells as key target in liver fibrosis

TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice